Physician profile
Matthew Mccarthy
NPI 1306917570
$2,119.71
in general payments reported to CMS, 2019-2025
18 companies · $928 in 2025
The $928 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.84 · 2023: $163 · 2024: $929 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.72 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $370.14 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $277.19 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $235.38 | 2023-2025 | |
| Axsome Therapeutics, INC. | $229.89 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $214.39 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.51 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $110.16 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $99.01 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $91.57 | 2024-2025 | Invega Sustenna, Spravato |
| E.R. Squibb & Sons, L.L.C. | $81.69 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $53.53 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Indivior INC. | $34.62 | 2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $29.21 | 2019 | |
| Mylan Specialty L.P. | $29.03 | 2024 | Yupelri |
| Novo Nordisk INC | $28.22 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.60 | 2024 | Trintellix |
| Exact Sciences Corporation | $19.58 | 2025 | The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $16.99 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.